Glaxis Capital Management’s Novo Nordisk NVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q4
Sell
-3,500
Closed -$417K 47
2024
Q3
$417K Sell
3,500
-6,500
-65% -$867K 1.62% 21
2024
Q2
$1.43M Buy
10,000
+1,000
+11% +$133K 2.46% 15
2024
Q1
$1.16M Sell
9,000
-1,000
-10% -$119K 2.14% 13
2023
Q4
$1.03M Buy
+10,000
New +$989K 3.6% 9

Other funds holding NVO

Glaxis Capital Management's NVO Position: Q4 2024 in Review

Glaxis Capital Management sold out of Novo Nordisk (NVO) in Q4 2024, closing a stake of 3,500 shares — an estimated $417K sold.

Glaxis Capital Management first reported a position in NVO in Q4 2023 and held it in 4 quarters. The position peaked at $1.43M in Q2 2024. 1,663 funds tracked by Wall St. Rank hold NVO as of Q4 2024.

  • Glaxis Capital Management reported no remaining Novo Nordisk position as of Q4 2024 after selling out during the quarter.
  • Glaxis Capital Management sold 3,500 Novo Nordisk shares in Q4 2024, an estimated $417K.
  • Glaxis Capital Management first reported a position in Novo Nordisk in Q4 2023 and held it in 4 quarters.
  • Glaxis Capital Management's Novo Nordisk position peaked at $1.43M in Q2 2024.
  • 1,663 funds tracked by Wall St. Rank held Novo Nordisk as of Q4 2024.

Based on Glaxis Capital Management's 13F filing for Q4 2024, filed 7 Feb 2025.